Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral propranolol for prevention of threshold retinopathy of prematurity
2024-511338-10-01Phase 2Authorised
- Sponsor
- Universitaetsklinikum Tuebingen AöR, Universität Zürich - Klinik für Neonatologie
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of propranolol in retinopathy of prematurity (ROP) (2 arms), sponsored by Universitaetsklinikum Tuebingen AöR, Universität Zürich - Klinik für Neonatologie. Primary endpoint: Survival without threshold retinopathy of prematurity. Planned start Oct 2024; status: authorised.
02
Drugs
propranolol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2024-511338-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511338-10-01.